These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21692314)

  • 21. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
    El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
    Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serogroup C meningococcal conjugate vaccines: new preparations. Effective from age two months.
    Prescrire Int; 2003 Apr; 12(64):43-6. PubMed ID: 12675020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
    Trotter CL; Gay NJ; Edmunds WJ
    Am J Epidemiol; 2005 Jul; 162(1):89-100. PubMed ID: 15961591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa.
    Okoko BJ; Idoko OT; Adegbola RA
    Vaccine; 2009 Mar; 27(14):2023-9. PubMed ID: 19095025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conjugate vaccine introduction in the African meningitis belt: meeting surveillance objectives.
    Mueller JE
    Trop Med Int Health; 2013 Jan; 18(1):58-64. PubMed ID: 23121399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection.
    Pace D
    Curr Opin Mol Ther; 2009 Dec; 11(6):692-706. PubMed ID: 20072946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meningococcal C conjugate vaccine: the experience in England and Wales.
    Campbell H; Borrow R; Salisbury D; Miller E
    Vaccine; 2009 Jun; 27 Suppl 2():B20-9. PubMed ID: 19477053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contributions of the Norwegian Institute of Public Health to the development of vaccines against serogroup B meningococcal disease.
    Rosenqvist E; Holst J; Nøkleby H
    Vaccine; 2007 Jan; 25(6):965-6. PubMed ID: 17052822
    [No Abstract]   [Full Text] [Related]  

  • 30. Neisseria meningitidis serogroup A vaccines: an overview.
    Vergnano S; Heath P
    Expert Rev Vaccines; 2003 Aug; 2(4):571-82. PubMed ID: 14711341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of bacterial meningitis: an overview of Cochrane systematic reviews.
    Prasad K; Karlupia N
    Respir Med; 2007 Oct; 101(10):2037-43. PubMed ID: 17706408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bacterial meningitis caused by Neisseria meningitidis. Prophylactic measures].
    Magdzik W
    Przegl Epidemiol; 2004; 58(2):241-51. PubMed ID: 15521103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serologic correlates of protection for evaluating the response to meningococcal vaccines.
    Balmer P; Borrow R
    Expert Rev Vaccines; 2004 Feb; 3(1):77-87. PubMed ID: 14761245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meningococcal serogroup B infections: a search for a broadly protective vaccine.
    Vermont CL; van den Dobbelsteen GP
    Expert Rev Vaccines; 2003 Oct; 2(5):673-81. PubMed ID: 14711328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Meningococcal disease in Africa--epidemiology and prevention].
    Norheim G; Rosenqvist E; Aavitsland P; Caugant DA
    Tidsskr Nor Laegeforen; 2000 Jun; 120(15):1735-9. PubMed ID: 10904659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2009 Apr; 35(ACS-3):1-40. PubMed ID: 19400026
    [No Abstract]   [Full Text] [Related]  

  • 38. The Meningitis Vaccine Project.
    LaForce FM; Konde K; Viviani S; Préziosi MP
    Vaccine; 2007 Sep; 25 Suppl 1():A97-100. PubMed ID: 17521780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.
    MacLennan J; Obaro S; Deeks J; Lake D; Elie C; Carlone G; Moxon ER; Greenwood B
    J Infect Dis; 2001 Jan; 183(1):97-104. PubMed ID: 11087205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of meningococcal serogroup C disease by NeisVac-C.
    Borrow R; Findlow J
    Expert Rev Vaccines; 2009 Mar; 8(3):265-79. PubMed ID: 19249967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.